From: Disease-modifying factors in hereditary angioedema: an RNA expression-based screening
Family code | Gender | Age | Arg472Stop | [C1-INH] (mg/dL) | C1-INH activity (% of NHP) | Symptoms | Treatment needed | Severity score | Severity degree |
---|---|---|---|---|---|---|---|---|---|
Family AR | |||||||||
ARO | F | 37 | Yes | 8.80 | 31.98 | Yes | Androgens | 43 | Severe |
AR2 | F | 64 | Yes | 6.84 | 25.11 | Yes | Androgens | 48 | Severe |
AR3 | M | 26 | Yes | 4.53 | 13.36 | Yes | Androgens | 48 | Severe |
AR4 | M | 60 | Yes | 7.51 | 25.06 | Yes | Androgens | 48 | Severe |
AR5 | F | 27 | Yes | <2.98 | 21.46 | Yes | No | 24 | Moderate |
AR7 | F | 60 | Yes | 5.81 | 18.21 | Yes | Androgens | 43 | Severe |
AR8 | F | 26 | Yes | 3.56 | 10.84 | Yes | Androgens | 49 | Severe |
AR9 | F | 40 | Yes | 3.79 | 18.28 | Yes | No | 12 | Mild |
AR10 | M | 53 | Yes | 7.05 | 34.24 | No | No | 0 | Asymptomatic |
AR11 | M | 30 | No | 22.30 | >100 | - | - | - | - |
AR12 | F | 56 | No | 19.90 | >100 | - | - | - | - |
AR13 | F | 44 | No | 25.30 | >100 | - | - | - | - |
AR14 | M | 51 | No | 23.90 | >100 | - | - | - | - |
AR15 | M | 52 | No | 18.70 | >100 | - | - | - | - |
AR16 | M | 45 | No | 25.80 | >100 | - | - | - | - |
AR17 | M | 47 | No | 25.30 | >100 | - | - | - | - |
Family DR | |||||||||
DR0 | F | 52 | Yes | 3.65 | 24.8 | Yes | No | 17 | Mild |
DR1 | M | 81 | Yes | 5.72 | 22.41 | No | ACE-i | 0 | Asymptomatic |
DR3 | M | 32 | Yes | 5.07 | 26.70 | No | No | 0 | Asymptomatic |
DR4 | M | 26 | Yes | 5.49 | 20.47 | No | No | 0 | Asymptomatic |
DR5 | F | 17 | No | 24.30 | >100 | - | - | - | - |
DR6 | M | 75 | No | 21.50 | >100 | - | - | - | - |
DR7 | M | 41 | No | 24.90 | >100 | - | - | - | - |
DR8 | F | 39 | No | 18.00 | >100 | - | - | - | - |
DR9 | F | 37 | No | 20.30 | >100 | - | - | - | - |
Family Q | |||||||||
Q0 | M | 82 | Yes | 4.11 | 10.68 | Yes | Androgens | 48 | Severe |
Q3 | F | 86 | Yes | 7.61 | 25.44 | No | No | 0 | Asymptomatic |
Q4 | F | 57 | Yes | 11.80 | 40.63 | Yes | Androgens | 26 | Moderate |
Q6 | F | 36 | Yes | 4.64 | 16.42 | Yes | Androgens | 49 | Severe |
Q7 | F | 50 | Yes | <2.98 | 9.76 | Yes | No | 25 | Moderate |
Q8 | F | 48 | Yes | 5.88 | 16.26 | Yes | No | 28 | Moderate |
Q9 | F | 24 | Yes | 3.27 | 14.92 | Yes | No | 48 | Severe |
Q10 | F | 71 | Yes | 6.28 | 17.23 | No | - | 0 | Asymptomatic |
Q11 | M | 56 | No | 21.30 | >100 | - | - | - | - |
Q12 | F | 44 | No | 16.05 | 86.99 | - | - | - | - |
Q13 | M | 38 | No | 26.40 | >100 | - | - | - | - |
Q14 | F | 47 | No | 20.30 | >100 | - | - | - | - |
Q15 | F | 75 | Yes | 6.34 | 18.00 | Yes | Androgens | 25 | Moderate |
Q16 | F | 40 | Yes | 4.78 | 26.70 | Yes | Androgens | 27 | Moderate |
Q17 | M | 45 | Yes | Yes | Androgens | 25 | Moderate |